Call us 24/7

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Cancer clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

23 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy before surgery (neoadjuvant phase), followed by pembrolizumab alone after surgery (adjuvant phase) in participants with resectable stage IIB or IIIA non-small cell lung cancer (NSCLC).

     

Coming soon

This is a trial in adult participants with unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy followed by pembrolizumab monotherapy. The primary hypothesis of the trial is that within each platinum doublet chemotherapy cohort, the percentage of participants who develop grade 3 or higher pneumonitis is ≤10 percent.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a phase II, open-label, multicenter study to evaluate the efficacy and the safety/tolerability of poziotinib in up to 174 patients with NSCLC exon 20 insertion mutations (87 patients with EGFR exon 20 insertion mutations and 87 patients with HER2 exon 20 insertion mutations).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

A phase 3 global, multi-center, open-label comparison of ipilimumab with and without intratumoral IMO-2125 in subjects with advanced melanoma who had confirmed disease progression while on nivolumab or pembrolizumab.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study examines the efficacy of Debio 1347 administered at the recommended Phase II dose of 80 mg in subjects with solid tumors harboring FGFR1-3 gene fusion/rearrangement. The study will include 3 cohorts of subjects comprising biliary tract cancer (Cohort 1), urothelial cancer (Cohort 2) and, in Cohort 3, all other solid tumor histologies not included in Cohorts 1-2, such as non-small cell lung cancer (NSCLC), head and neck cancer, thyroid cancer, oral cancer, breast cancer, prostate cancer and others but excluding primary brain tumors.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a phase III, open-label, randomized (2:1), controlled, international study for patients with MDS classified as RAEB-1, RAEB-2 or RAEB-t after failure of treatment with azacitidine (AZA) or decitabine (DAC).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This Phase 1 study is designed to assess the safety, tolerability, pharmacokinetics and anti-tumor effect of increasing doses of study drug SKI-G-801 in patients with relapsed or refractory Acute Myeloid Leukemia (AML) who are unresponsive to currently available therapies.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The purpose of this study is to evaluate whether copanlisib in combination with rituximab is superior to a placebo in combination with rituximab in prolonging progression free survival in some patients with relapsed indolent non-Hodgkin lymphoma.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is an open-label, multi-center, randomized, phase III study designed to compare the efficacy and safety of AM0010 in combination with FOLFOX versus FOLFOX alone in patients with metastatic adenocarcinoma of the pancreas who have progressed on one prior gemcitabine containing regimen.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The main purpose of this study is to compare the overall response rate (ORR) and overall survival (OS) of NKTR-214 combined with nivolumab to that of a tyrosine kinase inhibitor (TKI) monotherapy (sunitinib or cabozantinib) in intermediate and poor-risk participants with previously untreated advanced renal cell carcinoma (RCC).